Biomarker data from the fostroxacitabine bralpamide phase 1 study to be presented at the EASL Liver Cancer Summit
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that an e-poster entitled “Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver” will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit 3-4 February. The Abstract (PO-221) is available on the EASL website. For additional information, please contactMagnus Christensen, Interim CEO and CFO, Medivir ABTelephone: +46 8 5468